262 related articles for article (PubMed ID: 36900415)
1. Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in
Gaba F; Blyuss O; Tan A; Munblit D; Oxley S; Khan K; Legood R; Manchanda R
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900415
[TBL] [Abstract][Full Text] [Related]
2. Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis.
Wang Y; Song Z; Zhang S; Wang X; Li P
Eur J Surg Oncol; 2022 Jun; 48(6):1209-1216. PubMed ID: 35216860
[TBL] [Abstract][Full Text] [Related]
3. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
[TBL] [Abstract][Full Text] [Related]
4. Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.
Stjepanovic N; Villacampa G; Nead KT; Torres-Esquius S; Melis GG; Nathanson KL; Teule A; Brunet J; Y Cajal TR; Llort G; Dienstmann R; Rue M; Domchek SM; Balmaña J
Eur J Cancer; 2020 Jun; 132():53-60. PubMed ID: 32325420
[TBL] [Abstract][Full Text] [Related]
5. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis.
Marchetti C; De Felice F; Boccia S; Sassu C; Di Donato V; Perniola G; Palaia I; Monti M; Muzii L; Tombolini V; Benedetti Panici P
Crit Rev Oncol Hematol; 2018 Dec; 132():111-115. PubMed ID: 30447915
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
Michaelson-Cohen R; Gabizon-Peretz S; Armon S; Srebnik-Moshe N; Mor P; Tomer A; Levy-Lahad E; Paluch-Shimon S
Eur J Cancer; 2021 May; 148():95-102. PubMed ID: 33743487
[TBL] [Abstract][Full Text] [Related]
7. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.
Mavaddat N; Antoniou AC; Mooij TM; Hooning MJ; Heemskerk-Gerritsen BA; ; Noguès C; Gauthier-Villars M; Caron O; Gesta P; Pujol P; Lortholary A; ; Barrowdale D; Frost D; Evans DG; Izatt L; Adlard J; Eeles R; Brewer C; Tischkowitz M; Henderson A; Cook J; Eccles D; ; van Engelen K; Mourits MJE; Ausems MGEM; Koppert LB; Hopper JL; John EM; Chung WK; Andrulis IL; Daly MB; Buys SS; ; Benitez J; Caldes T; Jakubowska A; Simard J; Singer CF; Tan Y; Olah E; Navratilova M; Foretova L; Gerdes AM; Roos-Blom MJ; Van Leeuwen FE; Arver B; Olsson H; Schmutzler RK; Engel C; Kast K; Phillips KA; Terry MB; Milne RL; Goldgar DE; Rookus MA; Andrieu N; Easton DF; ; ;
Breast Cancer Res; 2020 Jan; 22(1):8. PubMed ID: 31948486
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
Rebbeck TR; Kauff ND; Domchek SM
J Natl Cancer Inst; 2009 Jan; 101(2):80-7. PubMed ID: 19141781
[TBL] [Abstract][Full Text] [Related]
9. Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer.
Straub MM; Podoll MB; David SN; Wiesner GL; Desouki MM
Ann Diagn Pathol; 2018 Oct; 36():28-30. PubMed ID: 30055521
[TBL] [Abstract][Full Text] [Related]
10. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
Kauff ND; Domchek SM; Friebel TM; Robson ME; Lee J; Garber JE; Isaacs C; Evans DG; Lynch H; Eeles RA; Neuhausen SL; Daly MB; Matloff E; Blum JL; Sabbatini P; Barakat RR; Hudis C; Norton L; Offit K; Rebbeck TR
J Clin Oncol; 2008 Mar; 26(8):1331-7. PubMed ID: 18268356
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy?
Grandi G; Perrone AM; Perrone A; Mandato VD; Comerci G; Sammarini M; Merisio C; Amadori A; Stefanetti M; Martinello R; Facchinetti F; De Iaco P;
Maturitas; 2021 Jan; 143():59-64. PubMed ID: 33308637
[TBL] [Abstract][Full Text] [Related]
12. Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy.
van Verschuer VM; Heemskerk-Gerritsen BA; van Deurzen CH; Obdeijn IM; Tilanus-Linthorst MM; Verhoef C; Schmidt MK; Koppert LB; Hooning MJ; Seynaeve C
Cancer Biol Ther; 2014 Apr; 15(4):371-9. PubMed ID: 24423863
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer.
Wei X; Sun L; Slade E; Fierheller CT; Oxley S; Kalra A; Sia J; Sideris M; McCluggage WG; Bromham N; Dworzynski K; Rosenthal AN; Brentnall A; Duffy S; Evans DG; Yang L; Legood R; Manchanda R
JAMA Netw Open; 2024 Feb; 7(2):e2355324. PubMed ID: 38334999
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Risk-Reducing Salpingo-Oophorectomy on Breast Cancer Incidence and Histopathological Features in Women with a
Stuursma A; van der Vegt B; Jansen L; Berger LPV; Mourits MJE; de Bock GH
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046756
[TBL] [Abstract][Full Text] [Related]
15. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
[TBL] [Abstract][Full Text] [Related]
16. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.
Gordhandas S; Norquist BM; Pennington KP; Yung RL; Laya MB; Swisher EM
Gynecol Oncol; 2019 Apr; 153(1):192-200. PubMed ID: 30661763
[TBL] [Abstract][Full Text] [Related]
17. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR
JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374
[TBL] [Abstract][Full Text] [Related]
18. Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations.
Solsky I; Chen J; Rebbeck TR
Gynecol Oncol; 2020 Feb; 156(2):363-376. PubMed ID: 31918993
[TBL] [Abstract][Full Text] [Related]
19. The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling.
Vencken PM; Kriege M; Hooning M; Menke-Pluymers MB; Heemskerk-Gerritsen BA; van Doorn LC; Collée MM; Jager A; van Montfort C; Burger CW; Seynaeve C
Cancer; 2013 Mar; 119(5):955-62. PubMed ID: 23165859
[TBL] [Abstract][Full Text] [Related]
20. Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.
Steenbeek MP; Harmsen MG; Hoogerbrugge N; de Jong MA; Maas AHEM; Prins JB; Bulten J; Teerenstra S; van Bommel MHD; van Doorn HC; Mourits MJE; van Beurden M; Zweemer RP; Gaarenstroom KN; Slangen BFM; Brood-van Zanten MMA; Vos MC; Piek JMJ; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; Massuger LFAG; IntHout J; Hermens RPMG; de Hullu JA
JAMA Oncol; 2021 Aug; 7(8):1203-1212. PubMed ID: 34081085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
